Advanced genomics and bioinformatics have fundamentally changed the way biotech science is performed. Sequencing projects that previously required years and tens of millions of dollars can now be completed in days for thousands of dollars. These developments have significantly lowered the barrier to entry for companies that develop biotech products. New species can now be quickly sequenced and analyzed for a multitude of attributes, enabling companies to select promising candidates at a much faster pace. Gathering important genomic information early in product development also greatly reduces investment risk — for example: potential products that may be genetically predisposed to disease or allergenicity can be eliminated early, freeing up valuable time and research dollars to be spent on the most promising candidates. Unfortunately, companies drawn by the promise of advanced genomics and bioinformatics are often met with new challenges and risks. Inexperienced teams may not have the necessary skills to design and manage genomics projects. Or they may lack the expertise to organize and evaluate data obtained from a sequencing project after it is completed. This is where a company like Analome can help. Analome harnesses the power of leading-edge genomics and bioinformatics to help clients accelerate product development. The team at Analome draws on decades of industry experience to help clients quickly design genomics projects and extract valuable insights with bioinformatics. The company also maintains an expert network of professionals and organizations in associated fields to further customize solutions depending on the unique needs of the client. “We make it easy for clients to target their R&D investment to the most promising new product candidates regardless of company size or project scope,” says David Kovalic, president of Analome. Analome begins each project by evaluating the needs and capabilities of the client. The results of this evaluation are used to craft a custom solution that provides the client with the appropriate skill sets and insights needed to complete the project. The expert team at Analome will also consult with clients across their entire pipeline, helping them to adopt and maintain best practices long after the initial engagement ends. .

A company proven to make novel enzyme development faster and more cost-effective, AUG-Met Bioinformatics modifies naturally occurring enzyme structures to create new biocatalysts. It achieves this by leveraging a neural network, which quantifies the correlations between enzymes and substrates to ensure the construction of final products more likely to elicit the desired reaction. Developing novel enzymes is typically a highly intricate and complex undertaking that involves selecting amino acids from a pool of 20 for each position in the protein sequence. This means filling in just one percent of an enzyme comprising upwards of 400 amino acids would require considering a staggering 160,000 possible combinations, making it practically impossible to test each in a laboratory setting. Traditionally, this process has relied on trial and error and expert knowledge to narrow the options, which can be time-consuming and expensive. Conversely, AUG-Met Bioinformatics’ neural network draws from existing enzymes to generate sequences based on enzymatic behavior and produce a range of potential sequences for the client to test in a laboratory setting. This simplifies the development process by significantly reducing the laboratory testing of sequences and providing clients with a faster and cost-effective means of obtaining enzymes with novel functions. Its methodology resembles Google Translate, but instead of languages, it converts enzymatic behavior into amino acid sequences. “We excel in connecting enzymatic reactions with their sequences through a correlation based on enzyme mechanics and backed by mathematical evidence. This enables us to offer prompt solutions to diverse client specifications,” says Thomas Philps, founder of AUG-Met Bioinformatics. AUG-Met Bioinformatics’ sequence specification feature allows clients to input areas of the sequence, eliminating the need for modifications. Its neural network then fills in the remaining sequence, considering the desired reaction. Clients can reliably generate enzyme sequences using a fill-in-the-blank method through this capability. All these unmatched capabilities are optional modules that clients can choose based on their unique requirements. AUG-Met Bioinformatics also provides enzymatic processes by inferring larger structures from subtle modifications in the substrate. A good example is its ability to phosphorylate lactose by generating enzyme sequences that account for the changes in substrate. This capability allows AUG-Met Bioinformatics to offer innovative solutions to clients seeking specific enzymatic modifications. .